Asia Pacific Colorectal Cancer Diagnostics Market Forecast to 2028
Asia Pacific Colorectal Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality [Imaging Tests (Colonoscopy, CT Colonography, Flexible Sigmoidoscopy, Capsule Endoscopy, and Others) and Stool-Based Tests (Faecal Immunochemical Test (FIT), Guaiac-Based Faecal Occult Blood Test, and Stool DNA Test)] and End User (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Prevalence of Colorectal Cancer Drives Asia Pacific Colorectal Cancer Diagnostics Market Growth
Colorectal cancer is a malignant tumor that develops in colonic or rectal tissues. Colorectal cancer is increasingly affecting populations in Asian countries. According to the International Agency for Research on Cancer & GLOBOCAN, ~1 million new colorectal cancer cases were reported in Asia in 2020. Japan, China, Malaysia, Singapore, Korea, and Turkey reported higher prevalence rates compared to other countries in Asia Pacific. Surgery is the most common treatment for all stages of colon cancer. In ideal situations, if the cancer is diagnosed in the early stages, doctors can remove the tumor via surgical procedures. A colonoscopy is an important screening test for colorectal cancer diagnostics, and it has become a part of routine cancer screening. Thus, the rising prevalence of colorectal cancer drives the growth of the Asia Pacific colorectal cancer diagnostics market .
Asia Pacific Colorectal Cancer Diagnostics Market Overview
The Asia Pacific colorectal cancer diagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Colorectal cancer (CRC) ranked third among China’s most diagnosed cancers in 2022, according to a study titled “Colorectal Cancer Screening in China: Status, Challenges, and Prospects.” As per GLOBOCAN, an estimated 555,477 newly diagnosed colorectal cancer cases and 286,162 colorectal cancer-related deaths occurred in China in 2020. With the aging population, socioeconomic developments, and lifestyle changes, the burden of colorectal cancer has increased in China in the past few decades, especially in urban and eastern regions. Numerous practices and studies have shown that early detection and treatment of CRC and its precancerous lesions through screening effectively reduces the mortality and incidence of CRC. Due to the large population and limited healthcare resources in China, a two-tier screening strategy has been adopted in most CRC screening programs. It is using a noninvasive or minimally invasive approach to select high-risk individuals and individuals who should undergo colonoscopy (the gold standard for CRC screening). Most guidelines in China recommend colonoscopy, flexible sigmoidoscopy, or faecal occult blood testing (mainly FIT) for people at average risk between the age of 50 and 75. Intestinal capsule endoscopy, computed tomography-colonography (CTC), and multi-target DNA have also been recommended in some guidelines or by consensus. In August 2022, Pillar Biosciences received approval from China’s National Medical Products Administration to commercialize its OncoReveal Dx Colon Cancer Assay. This approval was important to oncologists across China, who needed a streamlined, efficient, and accurate way to identify the right therapy for their patients.
Due to rapid socioeconomic development, environmental problems, lifestyle changes, and urbanization, people in China face several obstacles in maintaining and improving their health. The Chinese government has announced the Healthy China 2030 Plan, emphasizing the strategic importance of health for China’s growth. The growing investments in the health sector and an increasing prevalence of colon cancer are driving the growth of the Asia Pacific colorectal cancer diagnostics market in China.
Asia Pacific Colorectal Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Colorectal Cancer Diagnostics Market Segmentation
The Asia Pacific colorectal cancer diagnostics market is segmented into modality, end user, and country.
Based on modality, the Asia Pacific colorectal cancer diagnostics market is bifurcated into imaging tests and stool-based tests. In 2023, the imaging tests segment held a larger share of the Asia Pacific colorectal cancer diagnostics market. The market for the imaging tests segment is further segmented into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others. The market for the stool based tests segment is subsegmented into faecal immunochemical test (fit), guaiac-based faecal occult blood test (gFOBT), and stool DNA test.
Based on end user, the Asia Pacific colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. In 2023, the hospitals segment held the largest share of the Asia Pacific colorectal cancer diagnostics market.
Based on country, the Asia Pacific colorectal cancer diagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China accounted for the largest share of the Asia Pacific colorectal cancer diagnostics market.
Medtronic Plc, Illumina Inc, Epigenomics AG, Clinical Genomics Technologies Pty Ltd, F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc, Siemens Healthineers AG, Bruker Corp, and Eiken Chemical Co., Ltd. are the leading companies operating in the Asia Pacific colorectal cancer diagnostics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the Asia Pacific colorectal cancer diagnostic market was valued at US$ 2,461.75 million in 2023 and is expected to reach US$ 3,859.28 million by 2028, registering a CAGR of 9.4% from 2023 to 2028. Growing awareness of colorectal cancer and increasing prevalence of colorectal cancer are the critical factors attributed to the Asia Pacific colorectal cancer diagnostic market expansion.
A mass colorectal cancer screening program was conducted in Guangzhou, China, during 2015–2017. It used public media and mobile short message service (SMS) reminders to invite residents aged 50–74 to the screening program. Thus, the growing awareness about the effects of colorectal cancer on the quality of life would trigger the adoption of colonoscopy diagnostic procedures during the forecast period, thus offering lucrative opportunities to the market players.
On the contrary, low accuracy of screening based on faecal immunochemical tests (FITs) hurdles the growth of Asia Pacific colorectal cancer diagnostic market.
Based on modality, the Asia Pacific colorectal cancer diagnostics market is bifurcated into imaging tests and stool-based tests. The imaging tests segment held 95.6% share of Asia Pacific colorectal cancer diagnostic market in 2023, amassing US$ 2,353.35 million. It is projected to garner US$ 3,702.38 million by 2028 to expand at 9.5% CAGR during 2023–2028. The market for the imaging tests segment is further segmented into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others. The market for the stool based tests segment is subsegmented into faecal immunochemical test (fit), guaiac-based faecal occult blood test (gFOBT), and stool DNA test.
Based on end user, the Asia Pacific colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. The hospitals segment held 42.2% share of Asia Pacific colorectal cancer diagnostic market in 2023, amassing US$ 1,038.58 million. It is projected to garner US$ 1,669.38 million by 2028 to expand at 10.0% CAGR during 2023–2028.
Based on country, the Asia Pacific colorectal cancer diagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.5% share of Asia Pacific colorectal cancer diagnostic market in 2023. It was assessed at US$ 677.15 million in 2023 and is likely to hit US$ 1,080.93 million by 2028, exhibiting a CAGR of 9.8% during the forecast period.
Key players profiles in the Asia Pacific colorectal cancer diagnostic market report Medtronic Plc, Illumina Inc, Epigenomics AG, Clinical Genomics Technologies Pty Ltd, F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc, Siemens Healthineers AG, Bruker Corp, and Eiken Chemical Co., Ltd, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific colorectal cancer diagnostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific colorectal cancer diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the colorectal cancer diagnostics market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Colorectal Cancer Diagnostics Market – by Modality
1.3.2 Asia Pacific Colorectal Cancer Diagnostics Market – by End User
1.3.3 Asia Pacific Colorectal Cancer Diagnostics Market – by Country
2. Asia Pacific Colorectal Cancer Diagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Colorectal Cancer Diagnostics Market – Market Landscape
4.1 Overview
4.2 Asia Pacific PEST Analysis
4.3 Expert’s Opinion
5. Asia Pacific Colorectal Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Colorectal Cancer
5.1.2 Launches of New Products
5.2 Key Restraints
5.2.1 Low Accuracy of Screening Based on Faecal Immunochemical Tests (FITs)
5.3 Opportunities
5.3.1 Growing Awareness of Colorectal Cancer
5.4 Future Trends
5.4.1 Artificial Intelligence in Colonoscopy
5.5 Impact Analysis
6. Colorectal Cancer Diagnostics Market – Asia Pacific Analysis
6.1 Asia Pacific Colorectal Cancer Diagnostics Market Revenue Forecast and Analysis
6.2 Asia Pacific Colorectal Cancer Diagnostics Market, By Country – Forecast and Analysis
7. Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 – by Modality
7.1 Overview
7.2 Asia Pacific Colorectal Cancer Diagnostics Market Revenue Share, by Modality 2022 & 2028 (%)
7.3 Stool Based Tests
7.3.1 Overview
7.3.2 Stool Based Tests: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 Faecal Immunochemical Test (FIT)
7.3.3.1 Overview
7.3.3.2 Faecal Immunochemical Test (FIT): Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 Guaiac-based Faecal Occult Blood Test (gFOBT)
7.3.4.1 Overview
7.3.4.2 Guaiac-based Faecal Occult Blood Test (gFOBT): Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.5 Stool DNA Test
7.3.5.1 Overview
7.3.5.2 Stool DNA Test: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Imaging Tests
7.4.1 Overview
7.4.2 Imaging Tests: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.3 Colonoscopy
7.4.3.1 Overview
7.4.3.2 Colonoscopy: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.4 CT Colonography
7.4.4.1 Overview
7.4.4.2 CT Colonography: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.5 Flexible Sigmoidoscopy
7.4.5.1 Overview
7.4.5.2 Flexible Sigmoidoscopy: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.6 Capsule Endoscopy
7.4.6.1 Overview
7.4.6.2 Capsule Endoscopy: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.7 Others
7.4.7.1 Overview
7.4.7.2 Others: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 – by End User
8.1 Overview
8.2 Asia Pacific Colorectal Cancer Diagnostics Market Revenue Share, by End User 2022 & 2028 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Diagnostic Laboratories
8.4.1 Overview
8.4.2 Diagnostic Laboratories: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Cancer Research Institutes
8.5.1 Overview
8.5.2 Cancer Research Institutes: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 – Country Analysis
9.1 Overview
9.1.1.1 China: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 China: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.3 China: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.1.3.1 China: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.1.3.2 China: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.1.4 China: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.2 Japan: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Japan: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.3 Japan: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.2.3.1 Japan: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.2.3.2 Japan: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.2.4 Japan: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.3 India: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 India: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.3 India: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.3.3.1 India: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.3.3.2 India: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.3.4 India: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.4 Australia: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.4.1 Overview
9.1.1.4.2 Australia: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.4.3 Australia: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.4.3.1 Australia: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.4.3.2 Australia: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.4.4 Australia: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.5 South Korea: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.5.1 Overview
9.1.1.5.2 South Korea: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.5.3 South Korea: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.5.3.1 South Korea: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.5.3.2 South Korea: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.5.4 South Korea: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.6 Rest of Asia Pacific: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.6.1 Overview
9.1.1.6.2 Rest of Asia Pacific: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.6.3 Rest of Asia Pacific: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.6.3.1 Rest of Asia Pacific: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.6.3.2 Rest of Asia Pacific: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.6.4 Rest of Asia Pacific: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
10. Asia Pacific Colorectal Cancer Diagnostics Market–Industry Landscape
10.1 Overview
10.2 Inorganic Growth Strategies
10.2.1 Overview
10.3 Organic Growth Strategies
10.3.1 Overview
11. Company Profiles
11.1 Medtronic Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Illumina Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Clinical Genomics Technologies Pty Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Epigenomics AG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 F. Hoffmann-La Roche Ltd
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Quest Diagnostics Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Siemens Healthineers AG
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Bruker Corp
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Eiken Chemical Co., Ltd.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Colorectal Cancer Diagnostics Market –Revenue and Forecast to 2028 (US$ Million)
Table 2. China Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 3. China Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 4. China Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 5. China Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 8. Japan Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 9. Japan Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10. India Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 11. India Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 12. India Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 13. India Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 14. Australia Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 15. Australia Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 16. Australia Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 17. Australia Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 18. South Korea Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 19. South Korea Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 20. South Korea Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 21. South Korea Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Asia Pacific Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Asia Pacific Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Asia Pacific Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Asia Pacific Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 26. Recent Inorganic Growth Strategies in the Asia Pacific colorectal cancer diagnostics market
Table 27. Recent Organic Growth Strategies in the Asia Pacific colorectal cancer diagnostics market
Table 28. Glossary of Terms
LIST OF FIGURES
Figure 1. Asia Pacific Colorectal Cancer Diagnostics Market Segmentation
Figure 2. Asia Pacific Colorectal Cancer Diagnostics Market, by Country
Figure 3. Asia Pacific Colorectal Cancer Diagnostics Market Overview
Figure 4. Imaging Tests Segment Held Largest Share of Modality Segment in Asia Pacific Colorectal Cancer Diagnostics Market
Figure 5. India Expected to Show Remarkable Growth During Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Asia Pacific Colorectal Cancer Diagnostics Market Impact Analysis of Driver and Restraints
Figure 9. Asia Pacific Colorectal Cancer Diagnostics Market – Revenue Forecast and Analysis – 2020- 2028
Figure 10. Asia Pacific Colorectal Cancer Diagnostics Market Revenue Share, by Modality 2022 & 2028 (%)
Figure 11. Stool Based Tests: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Faecal Immunochemical Test (FIT): Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Guaiac-based Faecal Occult Blood Test (gFOBT): Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Stool DNA Test: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Imaging Tests: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Colonoscopy: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. CT Colonography: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Flexible Sigmoidoscopy: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Capsule Endoscopy: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Others: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Asia Pacific Colorectal Cancer Diagnostics Market Revenue Share, by End User 2022 & 2028 (%)
Figure 22. Hospitals: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Diagnostic Laboratories: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Cancer Research Institutes: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Others: Asia Pacific Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Asia Pacific: Colorectal Cancer Diagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 27. Asia Pacific: Colorectal Cancer Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 28. China: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Japan: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. India: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Australia: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. South Korea: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Rest of Asia Pacific: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
The List of Companies – Asia Pacific Colorectal Cancer Diagnostics Market
o Bruker Corp
o Clinical Genomics Technologies Pty Ltd
o Eiken Chemical Co., Ltd.
o Epigenomics AG
o F. Hoffmann-La Roche Ltd
o Illumina Inc
o Medtronic Plc
o Quest Diagnostics Inc
o Siemens Healthineers AG
You must be logged in to post a review.
Reviews
There are no reviews yet.